Table 3 The net benefit and the proportion of unnecessary biopsies reduced for PSAD, mpMRI, and the model in cohort 2
Risk threshold, % | Net benefit | Avoided biopsies | |||||
|---|---|---|---|---|---|---|---|
All biopsies | PSAD | MRI | Model | PSAD | MRI | Model | |
10 | 0.412 | 0.412 | 0.413 | 0.405 | 0 | 0.45% | −6.75% |
20 | 0.339 | 0.369 | 0.382 | 0.394 | 12.04% | 17.32% | 22.12% |
30 | 0.245 | 0.313 | 0.342 | 0.381 | 16.03% | 22.91% | 31.73% |
40 | 0.119 | 0.239 | 0.290 | 0.362 | 18.03% | 25.37% | 36.54% |